---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-26-000019"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2026-05-13T20:18:25+00:00"
generated_at: "2026-05-13T21:52:35.874391+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics reports Q1 net income of $24.1M on $36.8M license revenue; CATT1 enrollment on track

## Summary
- Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.
- Revenue of $36.8M from Newsoara license amendment; $20M upfront plus up to ~$115M milestones.
- Cash $98.1M at March 31, 2026, up from $88.9M; company says funds through CATT1 topline readout.
- Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes — enrollment on track for completion in Q3 2026.
- R&D expenses $9.0M (vs. $2.8M) driven by CATT1 trial investment; G&A $4.6M (vs. $3.7M).

## SEC filing metadata
- accession: 0001641489-26-000019
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2026-05-13T20:18:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/0001641489-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/vtvt-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-26-000019
- JSON: https://secwatch.observer/filing/0001641489-26-000019.json
- Plain text: https://secwatch.observer/filing/0001641489-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.